Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
NCIC Clinical Trials Group Identifier:
First received: February 5, 2003
Last updated: November 7, 2010
Last verified: March 2010

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or recurrent malignant melanoma.

Condition Intervention Phase
Melanoma (Skin)
Drug: perifosine
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma

Resource links provided by NLM:

Further study details as provided by NCIC Clinical Trials Group:

Study Start Date: June 2003
Study Completion Date: December 2009
Detailed Description:


  • Determine the efficacy of perifosine, in terms of response rate, in previously untreated patients with metastatic or recurrent malignant melanoma.
  • Assess the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral perifosine daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or partial response (PR) receive 2 additional courses after documentation of CR or stable PR (i.e., no further tumor shrinkage).

Patients are followed at 4 weeks and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed malignant melanoma
  • Metastatic or recurrent disease deemed incurable by standard therapies
  • Clinically and/or radiologically documented disease by at least 1 site that is unidimensionally measurable as follows:

    • At least 20 mm by x-ray or physical exam
    • At least 10 mm by spiral CT scan
    • At least 20 mm by non-spiral CT scan
    • Bone lesions are not considered measurable
    • Outside previously irradiated area unless evidence of progression or new lesions within irradiated field
  • No known brain metastases



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks


  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than upper limit of normal (ULN)
  • AST no greater than 2.5 times ULN


  • Creatinine no greater than ULN


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior allergic reactions to compounds of similar chemical or biological composition to perifosine
  • No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
  • No ongoing or active infection
  • No other concurrent uncontrolled medical illness, psychiatric illness, or social situation that would preclude study entry


Biologic therapy

  • At least 3 months since prior adjuvant immunotherapy
  • No prior immunotherapy for recurrent/metastatic disease


  • No prior chemotherapy (including regional therapy)
  • No other concurrent cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy (except for low-dose, nonmyelosuppressive radiotherapy)


  • At least 4 weeks since prior major surgery


  • No other concurrent anticancer therapy or investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00053781

Canada, Alberta
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada, T2N 4N2
Canada, Nova Scotia
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada, N6A 4L6
Princess Margaret Hospital at University Health Network
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2L-4M1
McGill University
Montreal, Quebec, Canada, H2W 1S6
Sponsors and Collaborators
NCIC Clinical Trials Group
National Cancer Institute (NCI)
Study Chair: Donald S. Ernst, MD, FRCPC London Regional Cancer Program at London Health Sciences Centre
  More Information

Additional Information:
Publications: Identifier: NCT00053781     History of Changes
Other Study ID Numbers: I156, CAN-NCIC-IND156, CDR0000269475
Study First Received: February 5, 2003
Last Updated: November 7, 2010
Health Authority: United States: Federal Government

Keywords provided by NCIC Clinical Trials Group:
recurrent melanoma
stage IV melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on October 06, 2015